Accolade (NASDAQ:ACCD) Announces Quarterly Earnings Results

Accolade (NASDAQ:ACCD) announced its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01, Briefing.com reports. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.57%. The company had revenue of $124.80 million for the quarter, compared to analysts’ expectations of $123.91 million. During the same period in the previous year, the company posted ($0.42) EPS. Accolade’s revenue was up 26.1% compared to the same quarter last year. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Stock Performance

Shares of ACCD stock traded down $1.30 during trading on Friday, hitting $7.89. The company’s stock had a trading volume of 1,491,193 shares, compared to its average volume of 585,879. The company has a market cap of $610.76 million, a PE ratio of -5.93 and a beta of 2.08. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average of $9.66 and a 200-day moving average of $9.91. Accolade has a 52 week low of $6.33 and a 52 week high of $17.00.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Piper Sandler increased their price objective on shares of Accolade from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Tuesday, January 9th. SVB Leerink began coverage on Accolade in a research note on Monday, February 26th. They set an “outperform” rating and a $16.00 target price for the company. Truist Financial reduced their price objective on Accolade from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday. Canaccord Genuity Group cut their target price on Accolade from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Raymond James raised their price target on Accolade from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Tuesday, January 9th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Accolade presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.80.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.